---
title: "Peering Into Haemonetics's Recent Short Interest"
description: "Haemonetics's HAE short percent of float has fallen 4.44% since its last report. The company recently reported that it has 3.50 million shares sold short, which is 11.84% of all regular shares that ar"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251882388.md"
published_at: "2025-08-06T17:39:49.000Z"
---

# Peering Into Haemonetics's Recent Short Interest

> Haemonetics's HAE short percent of float has fallen 4.44% since its last report. The company recently reported that it has 3.50 million shares sold short, which is 11.84% of all regular shares that are available for trading.

Haemonetics's HAE short percent of float has fallen 4.44% since its last report. The company recently reported that it has 3.50 million shares sold short, which is 11.84% of all regular shares that are available for trading.

### Related Stocks

- [HAE.US - Heamonetics](https://longbridge.com/en/quote/HAE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 分析 Heamonetics (HAE) 在近期股价疲软后的估值 | 海蒙尼克斯（Haemonetics，HAE）在经历了显著的股价下跌后吸引了投资者的关注，尽管其年度收入和净利润均实现了正增长。该股票目前交易价格为 57.76 美元，低于分析师的目标价，暗示其可能被低估，公允价值估计为 91.70 美元。公 | [Link](https://longbridge.com/en/news/276102791.md) |
| Skylands Capital LLC 在 Heamonetics 公司$HAE 持有价值 397 万美元的股票 | Skylands Capital LLC 在第三季度将其在 Haemonetics Corporation (NYSE:HAE) 的持股增加了 195.4%，目前持有 81,369 股，价值约为 397 万美元。其他机构投资者也增加了在 H | [Link](https://longbridge.com/en/news/275611703.md) |
| Mizuho Markets Americas LLC 持有 Heamonetics Corporation 价值 645 万美元的股份 | 瑞穗市场美洲公司在第三季度将其在海蒙尼克斯公司（NYSE:HAE）的持股减少了 43.9%，目前持有 132,314 股，价值 645 万美元。其他对冲基金也调整了他们的持仓。海蒙尼克斯报告第三季度每股收益为 1.27 美元，超出预期，收入 | [Link](https://longbridge.com/en/news/272973905.md) |
| EQT 将 Vivasure Medical 出售给 Heamonetics，交易金额最高可达 1.85 亿欧元 | 海蒙尼克斯公司已收购 Vivasure Medical Limited，交易金额最高可达 1.85 亿欧元，其中包括 1 亿欧元的预付款和最高 8500 万欧元的基于销售增长的后续付款。Vivasure 的 PerQseal Elite 系 | [Link](https://longbridge.com/en/news/272225988.md) |
| 海蒙尼蒂克斯在分析师眼中的地位如何 | 海蒙尼克斯（Haemonetics，NYSE:HAE）在过去三个月内获得了 11 位分析师的褒贬不一的评价，12 个月的平均目标价为 87.45 美元，较之前的目标上涨了 7.84%。近期的分析师行动包括巴林顿研究和瑞穗等公司的评级上调，目 | [Link](https://longbridge.com/en/news/272283620.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.